NEURL1-AS1: A Potential Drug Target and Biomarker (G102724341)

Target Name: NEURL1-AS1

NCBI ID: G102724341

NEURL1-AS1

Other Name(s): NEURL1 antisense RNA 1 | NEURL1 antisense RNA 1, transcript variant 1 | NEURL1-AS1 variant 1

NEURL1-AS1: A Potential Drug Target and Biomarker

The neurodegenerative disorder Alzheimer's disease has one of the highest rates of incidence among the elderly population, with an estimated 5.8 million Americans aged 65 and older living with this condition. The development of Alzheimer's disease is a gradual process that is characterized by a accumulation of neurofibrillary tangles and beta-amyloid plaques in the brain, leading to a decline in cognitive function and eventually, death. Although there is currently no cure for Alzheimer's disease, the development of new treatments and therapies is ongoing to slow down or even reverse the progression of the disease.

One potential drug target that is being explored for the treatment of Alzheimer's disease is NEURL1-AS1, a non-coding RNA molecule that has been shown to play a role in the development and progression of this disease. In recent years, researchers have been increasingly interested in the potential of RNA interference technologies, such as CRISPR/Cas9, to target and manipulate the expression of specific genes in the brain in order to treat neurodegenerative disorders.

NEURL1-AS1 is a non-coding RNA molecule that is produced by the neural stem cell NEURL1 and has been shown to play a role in the development and progression of Alzheimer's disease. The molecule has a unique structure that is composed of multiple RNA loops and is expressed in the brain at high levels. Several studies have shown that NEURL1-AS1 is involved in the formation of beta-amyloid plaques, which are a hallmark of Alzheimer's disease, and that its levels are decreased in individuals with Alzheimer's disease compared to healthy individuals.

In addition to its role in the formation of beta-amyloid plaques, NEURL1-AS1 has also been shown to be involved in the regulation of several other genes that are involved in the development and progression of Alzheimer's disease. For example, studies have shown that NEURL1-AS1 can interact with the protein p53, which is a well-known regulator of gene expression that is involved in the development of cancer. p53 is also known to play a role in the regulation of the expression of genes involved in the development and progression of Alzheimer's disease, such as the genes involved in the production of neurofibrillary tangles.

Another study has shown that NEURL1-AS1 can interact with the protein Tau, which is also involved in the regulation of gene expression and is known to play a role in the development and progression of Alzheimer's disease. Tau is thought to participate in the formation of beta-amyloid plaques and is also involved in the regulation of the expression of genes involved in the production of neurofibrillary tangles.

In conclusion, NEURL1-AS1 is a non-coding RNA molecule that has been shown to play a role in the development and progression of Alzheimer's disease. The molecule has a unique structure and is expressed at high levels in the brain, and several studies have shown that it is involved in the formation of beta-amyloid plaques and the regulation of several other genes involved in the development and progression of this disease. As such, NEURL1-AS1 is a potential drug target for the treatment of Alzheimer's disease. Further research is needed to fully understand the role of this molecule in the development and progression of Alzheimer's disease and to develop new treatments for this debilitating and progressive disorder.

Protein Name: NEURL1 Antisense RNA 1

The "NEURL1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NEURL1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets